<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758782</url>
  </required_header>
  <id_info>
    <org_study_id>CONSUL2016</org_study_id>
    <nct_id>NCT02758782</nct_id>
  </id_info>
  <brief_title>NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis</brief_title>
  <acronym>CONSUL</acronym>
  <official_title>COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the impact of treatment with a non-steroidal anti-inflammatory drug (NSAID) -
      Celecoxib - when added to anti-tumour necrosis factor (TNF) therapy - Golimumab - as compared
      to anti-TNF therapy (Golimumab) alone on progression of structural damage in the spine over
      two years in patients with ankylosing spondylitis (AS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the proposed trial is to evaluate the efficacy of combined treatment with a
      non-steroidal anti-inflammatory drug (NSAID) added to anti-tumour necrosis factor (TNF)
      therapy as compared to anti-TNF therapy alone on progression of structural damage in the
      spine over two years in patients with ankylosing spondylitis (AS). The trial consists of two
      phases. In the phase I (run-in phase), patients with active AS despite treatment with NSAIDs
      and elevated C-reactive protein will be included and treated with a TNF blocker (golimumab).
      Patients with good clinical response to golimumab at week 12 will be eligible for the phase
      II (core phase) of the study and will be randomized 1:1 to 1) golimumab + celecoxib
      (experimental intervention) for 2 years (weeks 12-108) or 2) golimumab alone (control
      intervention) also for 2 years. The primary outcome parameter will be the absolute
      progression of the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) - currently a
      standard of structural spinal damage progression evaluation in AS - over two years of therapy
      (weeks 12-108).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute progression of the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) over two years of therapy (weeks 12-108) in the Phase II (core phase) of the trial</measure>
    <time_frame>2 years</time_frame>
    <description>Absolute progression of the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) over two years of therapy (weeks 12-108) in the Phase II (core phase) of the trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New syndesmophyte formation or progression of existing syndesmophytes</measure>
    <time_frame>2 years</time_frame>
    <description>New syndesmophyte formation or progression of existing syndesmophytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of disease activity (BASDAI)</measure>
    <time_frame>2 years</time_frame>
    <description>Improvement of disease activity (BASDAI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of disease activity (ASDAS)</measure>
    <time_frame>2 years</time_frame>
    <description>Improvement of disease activity (ASDAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of function (BASFI)</measure>
    <time_frame>2 years</time_frame>
    <description>Improvement of function (BASFI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of axial mobility (BASMI)</measure>
    <time_frame>2 years</time_frame>
    <description>Improvement of axial mobility (BASMI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of quality of life measures (ASAS Health Index)</measure>
    <time_frame>2 years</time_frame>
    <description>Improvement of quality of life measures (ASAS Health Index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the enteric microbiome profile at week 108 in comparison to baseline</measure>
    <time_frame>2 years</time_frame>
    <description>Change of the enteric microbiome profile at week 108 in comparison to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Berlin MRI score (SUBSTUDY)</measure>
    <time_frame>2 years</time_frame>
    <description>Change of Berlin MRI score (SUBSTUDY)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AE), serious AE and AE of interest until end of study</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events (AE), serious AE and AE of interest until end of study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Ankylosing Spondylitis</condition>
  <arm_group>
    <arm_group_label>Golimumab monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with 50 mg Golimumab subcutaneous once monthly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Golimumab combined with Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Golimumab 50 mg subcutaneous once monthly in combination with Celecoxib 400 mg orally every day</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Golimumab</intervention_name>
    <arm_group_label>Golimumab monotherapy</arm_group_label>
    <arm_group_label>Golimumab combined with Celecoxib</arm_group_label>
    <other_name>Simponi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <arm_group_label>Golimumab combined with Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Definite diagnosis of AS according to the &quot;modified New York criteria&quot;.

          -  History of an inadequate response to ≥2 NSAIDs taken for at least 2 weeks each.

          -  Active disease as defined by a Bath Ankylosing Spondylitis Disease Activity Index
             (BASDAI) value of ≥4 at screening.

          -  Presence of at least one of the following risk factors for radiographic spinal
             progression:

               1. Elevated C reactive protein (CRP; &gt;5mg/l) at screening at the absence of reasons
                  for elevated CRP other than AS;

               2. Presence of ≥ 1 syndesmophyte on prior X-rays of the spine.

          -  Subject is a candidate for anti-TNF therapy based on the Investigator's opinion.

          -  Subject is able and willing to give a written informed consent and comply with the
             requirements of the study protocol. Only patients who give written informed consent
             will be included in the trial.

          -  If female: either unable to bear children (postmenopausal for at least 1 year or
             surgically sterile) or is willing and able to practice a reliable method of
             contraception throughout the study and 6 months after

        Inclusion Criterion for Phase II (randomized part of the study):

        - adequate response to Golimumab during Phase I (referred to as decline in BASDAI)

        Major Exclusion Criteria:

          -  For female subjects: pregnancy or lactating

          -  subjects with chronic inflammatory articular disease other than spondyloarthritis / AS
             or systemic autoimmune disease, e.g. systemic lupus erythematosus, Sjögren´s syndrome,
             rheumatoid arthritis.

          -  history of inadequate response to anti-TNF-therapy

          -  intolerability/hypersensitivity to one of the drugs or other components of the study
             medication

          -  presence ot total spinal ankylosis

          -  contraindications to anti-TNF-therapy (current or remitting clinical significant
             infections, tuberculosis, viral hepatitis, HIV; malignancies; demyelinating disease;
             vaccination with live vaccine within 3 months before, during and until 6 months after
             study)

          -  (relative) contraindications to Celecoxib therapy (uncontrolled arterial hypertension,
             high cardiovascular risk / history of cardiovascular events; history of
             gastrointestinal ulcers or relevant bleeding; known M. Crohn or ulcerative colitis)

          -  diagnosis of fibromyalgia

          -  significant lab abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Poddubnyy, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Dpt. for Rheumatology at Charite, Campus Benjamin Franklin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denis Poddubnyy, Prof. Dr.</last_name>
    <phone>+49-30-450</phone>
    <phone_ext>514544</phone_ext>
    <email>denis.poddubnyy@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Burkhard Muche, Dr.</last_name>
    <phone>+49-30-8445</phone>
    <phone_ext>4144</phone_ext>
    <email>burkhard.muche@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rheumapraxis Kupka</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kupka, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis Bayreuth Dr. Ochs</name>
      <address>
        <city>Bayreuth</city>
        <zip>95444</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ochs, Dr</last_name>
    </contact>
    <contact_backup>
      <last_name>Schmitt-Haendle, Dr</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin - Dpt. Rheumatology at Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burmester, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Feist, PD Dr</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Schwerpunktpraxis</name>
      <address>
        <city>Berlin</city>
        <zip>12161</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandt-Jürgens, PD Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Praxis Dr. Karberg/Brandt</name>
      <address>
        <city>Berlin</city>
        <zip>12163</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karberg, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin, Dpt. of Rheumatology at Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Burkhard Muche, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hildrun Haibel, PD Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valeria Rios Rodriguez, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Poddubnyy, Prof Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florian Proft, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis Dr. Remstedt</name>
      <address>
        <city>Berlin</city>
        <zip>12453</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remstedt, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MVZ Drs. Mielke</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mielke, Dr</last_name>
    </contact>
    <contact_backup>
      <last_name>Dörner, Prof</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis Dr. Zinke</name>
      <address>
        <city>Berlin</city>
        <zip>13055</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silke Zinke, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schlossparkklinik, Dpt. of Rheumatologie</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alten, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumatologische Schwerpunktpraxis an den Kreiskliniken</name>
      <address>
        <city>Burghausen</city>
        <zip>84489</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nigg, Dr</last_name>
    </contact>
    <contact_backup>
      <last_name>Feuchtenberger, Dr</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Uniklinik Düsseldorf, Rheumatologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schneider, Prof Dr</last_name>
    </contact>
    <contact_backup>
      <last_name>Richter, PD Dr</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centrum für innovative Diagnostik und Therapie Rheumatologie/Immunologie (CIRI)</name>
      <address>
        <city>Frankfurt / Main</city>
        <zip>60528</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Köhm, Dr</last_name>
    </contact>
    <contact_backup>
      <last_name>Behrens, Dr</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Praxis Dr Kühne</name>
      <address>
        <city>Haldensleben I</city>
        <zip>39340</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kühne, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule, Rheumatologie</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riechers, Dr</last_name>
    </contact>
    <contact_backup>
      <last_name>Witte, Prof</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet</name>
      <address>
        <city>Herne</city>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiltz, Dr</last_name>
    </contact>
    <contact_backup>
      <last_name>Baraliakos, Dr</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln, Rheumatologie</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Rubbert-Roth, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis Dipl.med. Aurich</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sieburg</last_name>
    </contact>
    <contact_backup>
      <last_name>Aurich, Dipl Med</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der ISAR (TU München)</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Moog, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis Dr. Jacki</name>
      <address>
        <city>Tübingen</city>
        <zip>72072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacki, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tuebingen, Dpt. Rheumatology</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Henes, PD Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Proft F, Muche B, Listing J, Rios-Rodriguez V, Sieper J, Poddubnyy D. Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) - an open-label randomized controlled multicenter trial. BMJ Open. 2017 Jun 10;7(6):e014591. doi: 10.1136/bmjopen-2016-014591.</citation>
    <PMID>28601821</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Denis Poddubnyy</investigator_full_name>
    <investigator_title>Prof Dr Denis Poddubnyy</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

